Active ingredients: miglustat
What it is used for
Zavesca is indicated for the oral treatment of patients with mild to moderate Type 1 Gaucher disease, for whom enzyme replacement therapy is not a therapeutic option. ZAVESCA is indicated for the treatment of the progressive neurological manifestations in adult and paediatric patients with Niemann-Pick type C disease.
How to take it
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
- The way to take this medicine: Oral
- Store below 30 degrees Celsius
- Lifetime is 5 Years.
Always read the label. If symptoms persist see your healthcare professional.
White capsule with "OGT918" printed in black on the cap and "100" printed on the body.
Do I need a prescription?
We are unable to tell you if you need a prescription for this medicine. You can ask your pharmacist.This medicine is
Pregnant or planning a pregnancy?
For the active ingredient miglustat
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
For side effects, taking other medicines and more
Download consumer medicine information leaflet (pdf)
Zavesca Capsules - myDr.com.au
Zavesca Capsules - Consumer Medicines Information leaflets of prescription and over-the-counter medicines
Read more on myDr – Consumer Medicine Information website
Gaucher Disease | myVMC
Gaucher disease(GD) is an inherited genetic disorder that leads to the build up of fatty deposits in multiple organs within the body, including the spleen, liver, bone marrow and, rarely, the brain
Read more on myVMC – Virtual Medical Centre website